Polyclonal antibody TriTAb

Drug Profile

Polyclonal antibody TriTAb

Alternative Names: Polyclonal antibody TriTAb - Protherics; TriTAb

Latest Information Update: 09 Oct 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Protherics
  • Class Antidotes; Polyclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Poisoning

Most Recent Events

  • 09 Oct 2001 Discontinued-II for Poisoning in USA (Unknown route)
  • 19 Dec 2000 Protherics have reaquired the distribution rights of TriTab from Altana in the USA
  • 18 Oct 1999 Therapeutic Antibodies has merged with Proteus International to form Protherics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top